FDAnews

ALLERGY THERAPEUTICS' RAGWEED VACCINE PASSES KEY TRIAL

Allergy Therapeutics' Pollinex Quattro Ragweed (PQR), a hay fever treatment, has passed a key Phase III clinical efficacy and safety trial. The initial trial results of the study demonstrated that PQR was well-tolerated and significantly reduced clinical symptoms compared with a placebo, said the group.

The Pollinex Quattro allergy vaccines, which require only four injections per year, have the potential to transform allergy treatment for the estimated 30m or more people in North America suffer from allergies to ragweed.